L
Lori Marini
Researcher at Harvard University
Publications - 13
Citations - 1277
Lori Marini is an academic researcher from Harvard University. The author has contributed to research in topics: Exome sequencing & Metastatic breast cancer. The author has an hindex of 7, co-authored 12 publications receiving 861 citations. Previous affiliations of Lori Marini include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson,Viktor A. Adalsteinsson,Gavin Ha,Gavin Ha,Samuel S. Freeman,Samuel S. Freeman,Atish D. Choudhury,Daniel G. Stover,Heather A. Parsons,Gregory Gydush,Sarah C. Reed,Denisse Rotem,Justin Rhoades,Denis Loginov,Denis Loginov,Dimitri Livitz,Daniel Rosebrock,Daniel Rosebrock,Ignaty Leshchiner,Jaegil Kim,Chip Stewart,Mara Rosenberg,Joshua M. Francis,Joshua M. Francis,Cheng-Zhong Zhang,Cheng-Zhong Zhang,Ofir Cohen,Ofir Cohen,Coyin Oh,Huiming Ding,Paz Polak,Paz Polak,Max Lloyd,Sairah Mahmud,Karla Helvie,Margaret S. Merrill,Rebecca A. Santiago,Edward P. O’Connor,Seong Ho Jeong,Rachel Leeson,Rachel M. Barry,Joseph F. Kramkowski,Zhenwei Zhang,Laura Polacek,Jens G. Lohr,Jens G. Lohr,Molly Schleicher,Emily Lipscomb,Andrea Saltzman,Nelly Oliver,Lori Marini,Adrienne G. Waks,Adrienne G. Waks,Lauren C. Harshman,Sara M. Tolaney,Eliezer M. Van Allen,Eric P. Winer,Nan Lin,Mari Nakabayashi,Mary-Ellen Taplin,Cory M. Johannessen,Levi A. Garraway,Todd R. Golub,Jesse S. Boehm,Nikhil Wagle,Nikhil Wagle,Gad Getz,Gad Getz,J. Christopher Love,J. Christopher Love,Matthew Meyerson +70 more
TL;DR: In this paper, a software called ichorCNA was proposed to quantitatively measure tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations.
Journal Article
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Gavin Ha,Samuel S. Freeman,Atish D. Choudhury,Daniel G. Stover,Heather A. Parsons,Gregory Gydush,Sarah C. Reed,Denisse Rotem,Justin Rhoades,Dimitri Livitz,Daniel Rosebrock,Ignaty Leshchiner,Jaegil Kim,Chip Stewart,Mara Rosenberg,Joshua M. Francis,Cheng-Zhong Zhang,Ofir Cohen,Coyin Oh,Paz Polak,Max Lloyd,Sairah Mahmud,Karla Helvie,Margaret S. Merrill,Rebecca A. Santiago,Edward P. O’Connor,Seong Ho Jeong,Joseph F. Kramkowski,Zhenwei Zhang,Laura Polacek,Jens G. Lohr,Molly Schleicher,Emily Lipscomb,Andrea Saltzman,Nelly Oliver,Lori Marini,Adrienne G. Waks,Lauren C. Harshman,Sara M. Tolaney,Eliezer M. Van Allen,Eric P. Winer,Nan Lin,Mari Nakabayashi,Mary-Ellen Taplin,Cory M. Johannessen,Levi A. Garraway,Todd R. Golub,Jesse S. Boehm,Nikhil Wagle,Gad Getz,Matthew Meyerson,Viktor A. Adalsteinsson,Denis Loginov,Huiming Ding,Rachel Leeson,Rachel M. Barry,John C Love +56 more
TL;DR: The authors provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.
Journal ArticleDOI
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre,Jonathan A. Nowak,Jonathan A. Nowak,Nicholas D. Camarda,Richard A. Moffitt,Arezou A. Ghazani,Arezou A. Ghazani,Arezou A. Ghazani,Mehlika Hazar-Rethinam,Srivatsan Raghavan,Jaegil Kim,Lauren K. Brais,Dorisanne Y. Ragon,Marisa W. Welch,Emma Reilly,Devin McCabe,Lori Marini,Lori Marini,Kristin Anderka,Karla Helvie,Karla Helvie,Nelly Oliver,Nelly Oliver,Ana Babic,Annacarolina da Silva,Annacarolina da Silva,Brandon Nadres,Emily E. Van Seventer,Heather A. Shahzade,Joseph P. St. Pierre,Kelly P. Burke,Kelly P. Burke,Thomas E. Clancy,Thomas E. Clancy,James M. Cleary,James M. Cleary,Leona A. Doyle,Leona A. Doyle,Kunal Jajoo,Kunal Jajoo,Nadine Jackson McCleary,Nadine Jackson McCleary,Jeffrey A. Meyerhardt,Jeffrey A. Meyerhardt,Janet E. Murphy,Kimmie Ng,Kimmie Ng,Anuj K. Patel,Anuj K. Patel,Kimberly Perez,Kimberly Perez,Michael H. Rosenthal,Michael H. Rosenthal,Douglas A. Rubinson,Douglas A. Rubinson,Marvin Ryou,Marvin Ryou,Geoffrey I. Shapiro,Geoffrey I. Shapiro,Ewa Sicinska,Stuart G. Silverman,Stuart G. Silverman,Rebecca J. Nagy,Richard B. Lanman,Deborah Knoerzer,Dean Welsch,Matthew B. Yurgelun,Matthew B. Yurgelun,Charles S. Fuchs,Levi A. Garraway,Gad Getz,Gad Getz,Jason L. Hornick,Jason L. Hornick,Bruce E. Johnson,Matthew H. Kulke,Matthew H. Kulke,Robert J. Mayer,Robert J. Mayer,Jeffrey W. Miller,Paul B. Shyn,Paul B. Shyn,David A. Tuveson,Nikhil Wagle,Jen Jen Yeh,William C. Hahn,Ryan B. Corcoran,Scott L. Carter,Brian M. Wolpin,Brian M. Wolpin +89 more
TL;DR: Using an integrated multidisciplinary biopsy program, it is demonstrated that real-time genomic characterization of advanced PDAC can identify clinically relevant alterations that inform management of this difficult disease.
Journal ArticleDOI
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Utthara Nayar,Ofir Cohen,Christian Kapstad,Christian Kapstad,Michael S. Cuoco,Adrienne G. Waks,Seth A. Wander,Corrie A. Painter,Samuel S. Freeman,Nicole S. Persky,Lori Marini,Karla Helvie,Nelly Oliver,Orit Rozenblatt-Rosen,Cynthia X. Ma,Aviv Regev,Aviv Regev,Eric P. Winer,Eric P. Winer,Nan Lin,Nan Lin,Nikhil Wagle +21 more
TL;DR: Activating HER2 mutations are shown to confer resistance to ER-directed therapies in patients with ER+ metastatic breast cancer, and these mutations conferred estrogen independence as well as resistance to tamoxifen, fulvestrant and the CDK4 and CDK6 inhibitor palbociclib.
Journal ArticleDOI
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Adrienne G. Waks,Ofir Cohen,Ofir Cohen,Bose Kochupurakkal,Dae Hyun Kim,Dae Hyun Kim,Connor E. Dunn,Jorge Buendia Buendia,Jorge Buendia Buendia,Seth A. Wander,Karla Helvie,Max Lloyd,Max Lloyd,Lori Marini,Melissa E. Hughes,Samuel S. Freeman,S. Percy Ivy,Joseph Geradts,Steven J. Isakoff,Patricia LoRusso,Viktor A. Adalsteinsson,Sara M. Tolaney,Sara M. Tolaney,Ursula A. Matulonis,Ursula A. Matulonis,Ian E. Krop,Ian E. Krop,Alan D. D'Andrea,Eric P. Winer,Eric P. Winer,Nan Lin,Nan Lin,Geoffrey I. Shapiro,Nikhil Wagle +33 more
TL;DR: Genomic reversion in BRCA1/2 was the most commonly observed mechanism of resistance, occurring in four of eight patients, and supporting RAD51 focus formation as a clinically useful biomarker.